Selpercatinib for RET fusion-positive non-small cell lung cancer. [PDF]
Aust Prescreuropepmc +1 more source
An emerging melody composed of the notes from structural variants - Comment on 'The fusion characteristics of RET fusion in pan-cancer among the Chinese population: A comprehensive genomic analysis' by Chen et al. [PDF]
Transl OncolWu L, Zhou Q, Lu C.
europepmc +1 more source
Targeting rare oncogenic mutations in resectable non-small cell lung cancer: emerging perioperative strategies. [PDF]
J Thorac DisHao S +6 more
europepmc +1 more source
Investigating perceived stress and pain reduction following brief Reiki sessions in high-stress communities: an exploratory study. [PDF]
Front PsycholMcCutcheon H, Habiya SK.
europepmc +1 more source
Acute severe hypocalcaemia after initiation of a selective RET-inhibitor in medullary thyroid cancer. [PDF]
Endocr OncolCheng L +7 more
europepmc +1 more source
The Utility of Tissue-Agnostic Drugs in Lung Cancer Treatment. [PDF]
Pharmaceut MedKong L +6 more
europepmc +1 more source
Salvador Dali: Design for the Three-Cornered Hat Ballet [PDF]
, 2012 Carter, Curtis
core +1 more source
Corrigendum to "Selpercatinib in Chinese patients with <i>RET</i>-fusion-positive non-small-cell lung cancer: updated efficacy and safety analysis from the LIBRETTO-321 phase II trial". [PDF]
Ther Adv Med Oncoleuropepmc +1 more source
LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC. [PDF]
Lung Cancer (Auckl)Lee ATM, Ou SI.
europepmc +1 more source
Case Report: Complete pathologic response to neoadjuvant immunotherapy-chemotherapy in a patient with RET fusion-positive non-small cell lung cancer. [PDF]
Front OncolWang Y +5 more
europepmc +1 more source